Kajian Interaksi Obat pada Resep Pasien Epilepsi Rawat Jalan di RSUD dr. Slamet Garut

Penulis

  • Risa Susanti Universitas Lambung Mangkurat
  • Asri Dewi Latiefah Universitas Garut
  • Rahayu Nafisah Universitas Garut

DOI:

https://doi.org/10.52434/jifb.v16i2.42775

Kata Kunci:

antiepilepsi, epilepsi, interaksi obat

Abstrak

Epilepsi adalah gangguan neurologis kronis yang ditandai dengan kejang berulang yang disebabkan oleh aktivitas listrik abnormal di otak. Perawatan epilepsi biasanya memerlukan penggunaan OAE (obat antiepilepsi) untuk waktu yang lama, baik secara monoterapi maupun dalam kombinasi. Penggunaan OAE bersama dengan obat lain dapat meningkatkan risiko interaksi obat, yang dapat memengaruhi efektivitas terapi dan keamanan pasien. Tujuan dari penelitian ini untuk menganalisis potensi interaksi obat pada pasien epilepsi rawat jalan di RSUD Dr. Slamet Garut selama periode Juli hingga Desember 2024. Metode yang digunakan adalah pendekatan deskriptif analitik dengan pendekatan retrospektif catatan medis. Teknik pengambilan sampel yang digunakan dalam penelitian ini adalah total sampling. Interaksi obat diidentifikasi menggunakan aplikasi Drug Interaction Checker seperti Medscape dan Drugs.com, dibantu dengan literatur tertulis seperti artikel-artikel terkait. Hasil identifikasi interaksi kemudian diklasifikasikan berdasarkan jenis interaksi dan tingkat keparahan. Hasil penelitian menunjukkan sebanyak 147 pasien epilepsi rawat jalan di RSUD dr. Slamet Garut mengalami potensi interaksi obat (66%). Potensi interaksi yang paling umum teridentifikasi adalah jenis interaksi farmakokinetik (81,4%) dan tingkat keparahan moderat (62,8%). Fenitoin dengan omeprazol, amlodipin, dan asam asetilsalisilat serta asam valproat dengan levetiracetam adalah beberapa obat yang paling sering berinteraksi satu sama lain.

Referensi

1. World Health Organization. who.int. 2024. Epilepsy. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy

2. Kementerian Kesehatan RI. Ikatan Dokter Anak Indonesia. Jakarta: Kementerian Kesehatan RI; 2017. p. 79 Pedoman nasional pelayanan kedokteran tata laksana epilepsi pada anak.

3. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. In: Epileptic Disorders. 2014. p. 409–31.

4. Erbaş B. Polypharmacy and potential drug interactions causing neurological symptoms in geriatric patients with epilepsy. Arch Epilepsy. 2022;28(3):106–12.

5. Yang LZ, Guo Y, Wang ZQ, Zhang CQ. A population-based analysis of the global burden of epilepsy across all age groups (1990-2021): utilizing the Global Burden of Disease 2021 data. Front Neurol. 2024;12(15):01–18.

6. Coste J, Bruno LM, Bentata LC, Mikaeloff Y, Bouilleret V. Prevalence, demographic and spatial distribution of treated epilepsy in France in 2020: a study based on the French national health data system. J Neurol. 2023;271(1):519–25.

7. Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: A systematic review and meta-analysis. Neurology. 2011;77(10):1005–12.

8. Perhimpunan Dokter Spesialis Saraf Indonesia. Pedoman tata laksana epilepsi. 6th ed. Surabaya: Airlangga University Press; 2019. 1–91 p.

9. Wijaya JS, Saing JH, Destariani CP. Politerapi anti-epilepsi pada penderita epilepsi anak. Cdk-284. 2020;47(3):191–4.

10. Khairani AF, Sejahtera DP, Fauzal IA. Strategi pengobatan epilepsi: monoterapi dan politerapi. Berk NeuroSains. 2019;18(3):115–9.

11. Tedyanto EH, Chandra L, Adam OM. Gambaran penggunaan obat anti epilepsi (OAE) pada penderita epilepsi berdasarkan tipe kejang di poli saraf Rumkital DR. Ramelan Surabaya. J Ilm Kedokt Wijaya Kusuma. 2020;9(1):77.

12. Bosak M, Słowik A, Iwańska A, Lipińska M, Turaj W. Co-medication and potential drug interactions among patients with epilepsy. Seizure. 2019;66:47–52.

13. Birru EM, Shafi M, Geta M. Drug therapy of epileptic seizures among adult epileptic outpatients of University of Gondar referral and teaching hospital, Gondar, North West Ethiopia. Neuropsychiatr Dis Treat. 2016;12:3213–9.

14. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Vol. 61, British Journal of Clinical Pharmacology. 2006.

15. Etikan I. Comparison of convenience sampling and purposive sampling. Am J Theor Appl Stat. 2016;5(1):1–4.

16. Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326–31.

17. Charlier B, Coglianese A, de Rosa F, de Grazia U, Operto FF, Coppola G, et al. The effect of plasma protein binding on the therapeutic monitoring of antiseizure medications. Pharmaceutics. 2021;13(8):1208.

18. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Vol. 49, Epilepsia. 2008. p. 1239–76.

19. Adams CD. Stockley’s drug interactions. tenth edition, stockley’s drug interactions pocket companion 2013. Vol. 102, Journal of the Medical Library Association. 2014. 221 p.

20. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, et al. Clinical pharmacogenetics implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021;109(6):1417–23.

21. Erker T, Brandt C, Tollner K, Schreppel P, Twele F, Schidlitzki A, et al. The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice. Epilepsia. 2016;57(5):698–705.

22. Gunawan, Gan S. Farmakologi dan terapi edisi 6. In: Farmakologi dan Terapi Edisi 6. 6th ed. Fakultas Kedokteran Universitas Mulawaran; 2016. p. 932.

23. Patel KA, Bhatt MH, Hirani R V., Patel VA, Patel VN, Shah GB, et al. Assessment of potential drug–drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon. 2022;8(11):1–9.

24. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2005;61(3):246–55.

25. Drug.com. drug.com. 2025. Drug Interactions between levetiracetam and Valproate Sodium. Available from: https://www.drugs.com/drug-interactions/levetiracetam-with-valproate-sodium-1448-0-2286-17497.html?professional=1 https://www.fortyouncewines.com/ https://www.surreyhillschallenge.com/gallery

Unduhan

Diterbitkan

2025-07-31

Terbitan

Vol 16 No 2 (2025): Jurnal Ilmiah Farmako Bahari

Bagian

Research Article

Lisensi

Hak Cipta (c) 2025 Jurnal Ilmiah Farmako Bahari

Creative Commons License

Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

or all articles published in Jurnal Ilmiah Farmako Bahari, the copyright is retained by the journal. Articles are published under the terms of Creative Commons Attribution-ShareAlike 4.0 International License (CC-BY-SA 4.0) .

For Authors:

  • Any article on the copyright is retained by the author(s).
  • The author grants the journal, right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles of work (eg, post-institutional repository) or publish it in a book, with acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process, as can lead to productive exchanges, as well as earlier and greater citation of published work.
  • The article and any associated published material is distributed under the Creative Commons Attribution-ShareAlike 4.0 International License

Artikel Serupa

1 2 3 4 5 6 7 > >> 

Anda juga bisa Mulai pencarian similarity tingkat lanjut untuk artikel ini.